Lamotrigine generated real excitement in the early 2000s as a potential treatment for borderline personality disorder, but the picture has grown considerably murkier since then. Small studies suggested it could calm emotional volatility and reduce impulsive behavior, yet the largest and most rigorous trial to date found essentially no difference between lamotrigine and a placebo. The story of lamotrigine and BPD is less a clean success or failure and more a case study in how promising early findings sometimes fall apart at scale, with a few lingering questions that keep the drug in the conversation.
Why Lamotrigine Seemed Like a Good Fit
Lamotrigine was originally developed as an anticonvulsant for epilepsy and later approved as a mood stabilizer for bipolar disorder. The logic behind trying it in BPD was straightforward: if emotional instability is one of the hallmark features of borderline personality disorder, a drug known to smooth out mood swings in bipolar disorder might do something similar. At a brain-chemistry level, lamotrigine works primarily by blocking voltage-dependent sodium channels, which dampens excessive neuronal firing. It also reduces the release of glutamate, the brain’s main excitatory neurotransmitter, and may enhance inhibitory signaling.1PubMed Central. Understanding Lamotrigine’s Role in the CNS and Possible Future Evolution In theory, dialing down that excitatory activity could help with the emotional reactivity and impulsive surges that people with BPD experience.
An early open case series in the late 1990s added fuel to the optimism. Researchers treated a small group of BPD patients who did not have a co-occurring major mood disorder, and among those who responded, impulsive sexual behavior, drug-taking, and suicidal behaviors disappeared entirely, to the point where those patients no longer met diagnostic criteria for BPD.2PubMed. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder Results that dramatic from an uncontrolled case series need to be taken with a large grain of salt, but they were enough to justify more structured research.
The Small Trials That Built the Case
After those early observations, a handful of small randomized controlled trials tested lamotrigine more formally. One notable study specifically targeted affective instability, which is the rapid, intense emotional shifting that distinguishes BPD from ordinary mood fluctuations. Patients receiving lamotrigine showed significantly greater improvement on a standardized measure of emotional lability compared to those receiving a placebo. The same study also found improvements in general impulsivity.3International Clinical Psychopharmacology. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder
These results were encouraging enough that reviews of the BPD pharmacotherapy literature began to highlight lamotrigine as one of the more promising options. A comprehensive review noted that the drug’s mechanism of action, particularly its effects on glutamate and mood stabilization, aligned well with therapeutic goals for BPD.4PubMed Central. The Therapeutic Role of Lamotrigine in Borderline Personality Disorder: A Comprehensive Review of Outcomes, Mechanisms, and Treatment Strategies The UK’s NICE guidelines acknowledged this, noting that small-scale studies of lamotrigine and topiramate had produced “encouraging results,” though they explicitly called for a larger randomized placebo-controlled trial to settle the question.5British Journal of Medical Practitioners. A review of NICE guidelines on the management of Borderline Personality Disorder
The LABILE Trial Changed the Conversation
That larger trial arrived. Known as the LABILE trial, it was a well-designed, multi-site study in the UK that enrolled 276 people with BPD and randomly assigned them to lamotrigine or placebo, on top of their usual care. The follow-up lasted a full year, much longer than the earlier studies, which had typically run for only eight to twelve weeks. The results were strikingly negative.
After 52 weeks, the average BPD symptom scores in the two groups were nearly identical. The lamotrigine group scored an average of 11.3 on the ZAN-BPD scale, a widely used measure of borderline symptoms, while the placebo group scored 11.5. That gap of 0.2 points was statistically meaningless and clinically irrelevant.6PubMed. The Clinical Effectiveness and Cost-Effectiveness of Lamotrigine in Borderline Personality Disorder: A Randomized Placebo-Controlled Trial None of the secondary outcomes, including depression, self-harm, social functioning, and quality of life, showed any significant differences either. The healthcare costs were also similar between the two groups. The researchers concluded bluntly that adding lamotrigine to standard care for people with BPD was “not a clinically effective or cost-effective use of resources.”7PubMed Central. Lamotrigine for people with borderline personality disorder: a RCT
One important detail: only about a third of participants assigned to lamotrigine were still taking it at the 52-week mark. Low adherence is a real-world problem with many psychiatric medications, but it makes it harder to draw firm conclusions about what the drug itself does versus what happens when people sporadically take it. The researchers used standard statistical methods to account for this, and the results still showed no benefit, but some clinicians have pointed to adherence as a complicating factor worth acknowledging.
What the Meta-Analyses Say
When researchers pool data across multiple trials, the picture does not get much clearer. A systematic review and meta-analysis that examined lamotrigine’s effect on impulsivity and aggression across three randomized trials found no statistically significant difference between lamotrigine and placebo.8PubMed Central. Efficacy and Tolerability of Lamotrigine in Borderline Personality Disorder: A Systematic Review and Meta-Analysis That said, there was enormous variability between the individual studies, which makes pooled results harder to interpret. When studies produce wildly different effect sizes, averaging them together can obscure real effects in subgroups or specific symptom domains.
A more recent network meta-analysis, which compared multiple drug classes head-to-head using indirect evidence from different trials, reached a more nuanced conclusion. It found that lamotrigine in doses of 50 to 200 milligrams per day, when used over about eight weeks, was among the more effective options specifically for reducing hostility, aggressiveness, and anger, alongside topiramate and aripiprazole. The evidence for lamotrigine in this domain was rated as moderate.9PubMed. Efficacy and safety of pharmacological treatments in borderline personality disorder: A systematic review and network meta-analysis This suggests that lamotrigine might help with specific anger-related symptoms in the short term, even if it does not improve the broader BPD picture over a full year.
The tension between these findings reflects a genuine disagreement in the field. Short-term small trials tend to show benefits for targeted symptoms. The longest and largest trial shows no overall benefit. Whether this means lamotrigine helps briefly and then stops, or helps only a subset of patients, or only affects certain symptoms that wash out in composite scores, remains genuinely unresolved.
No Drug Is Approved for BPD
It is worth stepping back to acknowledge that no medication of any kind has regulatory approval for treating borderline personality disorder. Not lamotrigine, not any antidepressant, not any antipsychotic. This is unusual for such a common psychiatric condition. Psychotherapy, particularly dialectical behavior therapy and mentalization-based therapy, remains the first-line treatment with the strongest evidence base. Drugs, when used, are prescribed off-label for specific symptoms.
Despite this, medication prescribing for people with BPD is extremely common. A large study of prescribing trends in Spain found that pharmacotherapy was far more prevalent in BPD patients than clinical guidelines recommend.10PubMed. Twenty-Year Trends in the Psychopharmacological Treatment of Outpatients with Borderline Personality Disorder: A Cross-Sectional Naturalistic Study in Spain This reflects a reality that many clinicians and patients know well: BPD symptoms can be so disabling that clinicians feel compelled to try pharmacological options even when the evidence is thin, because doing nothing also feels inadequate. That pressure to “do something” is part of what keeps drugs like lamotrigine in the prescribing conversation even after disappointing trial results.
Where BPD and Bipolar Disorder Overlap
One factor that complicates the lamotrigine-BPD question is diagnostic overlap with bipolar disorder. The two conditions share surface-level features, particularly emotional instability and impulsive behavior, and they co-occur more often than chance alone would predict. Some patients carry both diagnoses. Lamotrigine is an established treatment for bipolar disorder, particularly for preventing depressive episodes, so when someone has both conditions, the drug may pull double duty.
Research on this overlap found that in patients with bipolar disorder who also had borderline personality traits, lamotrigine treatment was associated with significant improvement in those borderline dimensions. The improvement in BPD traits tracked alongside improvement in bipolar symptoms.11PubMed. Borderline personality disorder in patients with bipolar disorder and response to lamotrigine This raises an important question: when a patient with both diagnoses improves on lamotrigine, is the drug treating BPD directly, or is it treating the underlying bipolar disorder, and the BPD-like symptoms improve as a consequence? That distinction matters both for understanding the drug’s mechanism and for deciding whom to prescribe it to.
If you carry both diagnoses, or if your clinician suspects bipolar features underneath your BPD presentation, lamotrigine is on much stronger scientific footing. Its approval for bipolar maintenance is well established, and any spill-over benefit for borderline traits would be a bonus. If BPD is the primary and sole diagnosis, the evidence is far weaker.
Practical Considerations if You Are Prescribed It
Regardless of the mixed evidence, some clinicians still prescribe lamotrigine for BPD, especially when other approaches have not worked or when anger and emotional reactivity are the dominant symptoms. If your doctor has suggested it or you are already taking it, there are a few practical things worth knowing.
Lamotrigine must be started at a very low dose and increased slowly over several weeks. This is non-negotiable because of the risk of a rare but serious skin reaction called Stevens-Johnson syndrome, which is far more likely with rapid dose escalation. The standard titration schedule starts at 25 milligrams per day and works upward over about five to six weeks. Do not skip this step or try to speed it up because you are impatient for effects. The dose range used in BPD trials was typically 50 to 200 milligrams per day.
The drug is processed in the liver through a specific metabolic pathway, and other medications can significantly alter how quickly your body breaks it down. Drugs that speed up liver enzymes, such as carbamazepine and certain other anticonvulsants, can reduce lamotrigine levels enough to make it ineffective. Valproate does the opposite, slowing clearance and raising lamotrigine to potentially dangerous levels, roughly doubling the concentration in blood. If you take valproate alongside lamotrigine, the dose must be adjusted downward.
One interaction that often catches people off guard: lamotrigine can reduce the effectiveness of hormonal birth control. If you rely on the pill, patch, or ring for contraception, this is a conversation to have with your prescriber. And the interaction goes both ways. Estrogen-containing contraceptives can lower lamotrigine levels, so starting or stopping birth control might affect how well the drug works or whether side effects emerge.
Common Side Effects and Tolerability
Compared to many psychiatric medications, lamotrigine’s side-effect profile is relatively mild for most people. The most frequently reported issues include headache, dizziness, nausea, and mild cognitive complaints like difficulty finding words. Unlike antipsychotics, it does not typically cause significant weight gain, which matters because many BPD patients cycle through multiple medications and cumulative weight gain becomes a real quality-of-life issue. Unlike SSRIs, it does not tend to cause sexual dysfunction.
The serious concern is the skin reaction mentioned earlier. Any new rash that develops during the first few months of treatment needs immediate medical evaluation. Most rashes that appear on lamotrigine are benign, but distinguishing a harmless rash from the early stages of Stevens-Johnson syndrome is difficult without a clinical assessment. The risk drops substantially when the drug is titrated slowly and when the patient is not also taking valproate.
In the LABILE trial, the overall side-effect burden was similar between the lamotrigine and placebo groups, which is consistent with the drug being generally well tolerated.12PubMed Central. Lamotrigine for people with borderline personality disorder: a RCT The problem was not that the drug caused harm; it just did not produce measurable benefit.
How Lamotrigine Compares to Other Medications for BPD
Given the underwhelming evidence for lamotrigine, you might wonder what other pharmacological options have stronger support. The honest answer is that no drug has overwhelming evidence for BPD, but a few have slightly better data for specific symptom clusters.
The network meta-analysis that evaluated multiple drugs found that topiramate, at doses of 200 to 250 milligrams per day, had the strongest evidence for reducing hostility and anger, rated as high certainty. Aripiprazole, a second-generation antipsychotic, showed moderate evidence for the same symptom domain. On the other end of the spectrum, alprazolam, methylphenidate, haloperidol, and valproate had only low-certainty evidence and were not recommended as priorities.13PubMed. Efficacy and safety of pharmacological treatments in borderline personality disorder: A systematic review and network meta-analysis
Topiramate comes with its own problems, including cognitive dulling that patients often describe as a “brain fog” effect, along with weight loss that can be welcome for some but dangerous for others. Aripiprazole has a more established side-effect profile from its use in other conditions, including potential weight gain and metabolic effects, though these tend to be milder than with older antipsychotics. Neither drug is FDA-approved for BPD either.
The broader pattern across BPD pharmacotherapy is one of modest effects, limited trials, and no clear winners. Clinicians often end up trying multiple medications sequentially, targeting whichever symptoms are most impairing at a given time. This pragmatic approach reflects the reality of treating a condition where the evidence base for any single drug is thin.
Why the Research Keeps Going Back and Forth
If you find the evidence contradictory, you are reading it correctly. There are several reasons why BPD drug studies produce inconsistent results. First, BPD is a heterogeneous condition. Two people with the same diagnosis can have very different symptom profiles: one might struggle primarily with anger and impulsive aggression, while another’s core problem is emptiness, fear of abandonment, and self-harm. A drug that helps the first person might do nothing for the second, and if both are in the same trial, the average effect is diluted.
Second, the placebo response in BPD trials tends to be substantial. People with BPD often improve simply from the structure, attention, and hope that comes with being enrolled in a clinical trial, especially when they are also receiving psychotherapy as part of their usual care. This makes it harder for any active drug to outperform placebo.
Third, the earlier positive studies were small, often enrolling fewer than 30 patients per group. Small trials are statistically noisy and prone to inflated effect sizes. When a larger, better-powered trial comes along and finds nothing, the field has to reconcile those results. This is not unique to lamotrigine or BPD; it is a recurring pattern across psychiatry and medicine generally.
When BPD Symptoms Improve Without Medication
Something that rarely comes up in discussions about BPD pharmacotherapy is that the disorder itself tends to improve over time for many people, even without medication. Longitudinal studies have consistently shown that the most dramatic symptoms, including impulsive behavior, self-harm, and intense interpersonal conflict, tend to diminish with age. This does not mean BPD goes away or that everyone improves equally, and chronic feelings of emptiness and identity disturbance often persist longer than the more behavioral symptoms.
This natural trajectory complicates long-term medication decisions. If someone starts lamotrigine and gradually feels better over two or three years, it can be nearly impossible to know whether the drug is helping or whether their BPD was improving on its own. Stopping the medication to test this is understandably scary for someone who has struggled with the condition. There is no good research specifically on discontinuing lamotrigine in BPD patients, so these decisions tend to be made on a case-by-case basis between patient and clinician, balancing the uncertainty of the evidence against the psychological cost of changing a regimen that feels like it is working.